Oncology

Defying cancer

Our defiant goal is to reverse the cancer mortality trend. We’re doing this through a comprehensive pipeline that addresses the hallmarks of cancer. With an emphasis on immuno-oncology and antibody drug conjugates (ADCs), we are applying multiple approaches to activate the immune system to search and destroy cancer, and delivering highly-potent warheads directly to the tumor cell.




Our Pipeline

Oncology

Phase 1

Phase 1

  • Imfinzi + Iressa non-small cell lung cancer
  • Imfinzi + MEDI0562 solid tumours
  • Imfinzi + MEDI9197 solid tumours
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + dabrafenib + trametinib melanoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + chemotherapy 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • Imfinzi or Imfinzi + (tremelimumab or danvatirsen) diffuse large B-cell lymphoma
  • MEDI0562 solid tumours
  • MEDI1873 solid tumours
  • MEDI2228 multiple myeloma
  • MEDI3726 prostate cancer
  • MEDI5083 solid tumours
  • MEDI5752 solid tumours
  • MEDI7247 haematological malignancies
  • MEDI9197 solid tumours
  • oleclumab solid tumours
  • oleclumab + AZD4635 EGFRm NSCLC
  • oleclumab + Tagrisso EGFRm NSCLC
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • Imfinzi solid tumours
  • Imfinzi + AZD5069 or Imfinzi + danvatirsen head and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + MEDI0680 solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer

Phase 3

Phase 3

  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab EAGLE 2nd-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab MYSTIC 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + CRT ADRIATIC LD-SCLC
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi + tremelimumab + chemo POSEIDON 1st-line non-small cell lung cancer
  • Lumoxiti (moxetumomab ) pasudotox PLAIT 3rd-line hairy cell leukaemia

LCM Projects

LCM Projects

  • Imfinzi PACIFIC locally advanced (stage III) NSCLC
  • Imfinzi PEARL (China) 1st-line non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) NSCLC

Oncology News

Join us at MedImmune

Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.